Andreas Hollenstein

Title: The Innovations of Andreas Hollenstein

Introduction

Andreas Hollenstein is a notable inventor based in Utrecht, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. With a total of 4 patents to his name, Hollenstein's work is paving the way for advancements in cancer treatment and other diseases.

Latest Patents

Hollenstein's latest patents focus on bispecific anti-CD37 antibodies and monoclonal anti-CD37 antibodies. These inventions involve CD37-specific bispecific antibody molecules that bind to different epitopes of the human CD37 antigen. The bispecific antibody molecules exhibit enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. Additionally, the inventions relate to the monoclonal parental antibodies from which the binding regions of the bispecific antibody molecules are derived. Furthermore, these patents encompass pharmaceutical compositions containing these molecules and their application in treating cancer and other diseases.

Career Highlights

Andreas Hollenstein is currently associated with Genmab Holding B.V., a leading biotechnology company. His work at Genmab has been instrumental in advancing therapeutic solutions that target specific antigens, thereby improving treatment efficacy for patients.

Collaborations

Hollenstein collaborates with talented professionals in his field, including Simone Oostindie and Frank Beurskens. These collaborations enhance the innovative potential of his research and contribute to the success of their projects.

Conclusion

Andreas Hollenstein's contributions to the field of biotechnology through his patents on bispecific antibodies are significant. His work not only showcases his expertise but also holds promise for future advancements in cancer treatment.